Persantine: Variation in Response Trial

UConn Health

Status and phase

Terminated

Phase 4

Conditions

Coronary Artery Disease

Treatments

Drug: dipyridamole

Study type

Interventional

Funder types

Other

Other U.S. Federal agency

Identifiers

NCT00763009

A-13147.1

02-202-1

Details and patient eligibility

About

The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.

Full description

Participants will receive three doses of Persantine intravenously for the research study. Before and after receiving the Persantine doses, patients will have an echocardiogram and coronary artery blood flow will be measured. Blood tests,measure the function of the adenosine transporter. In addition variations in the gene for the adenosine transporter will be evaluated.

Enrollment

8 patients

Sex

All

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients > 21 years old
Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex

Exclusion criteria

Theophylline or oral Persantine use in 24hrs
Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
Active asthma or bronchospasm
Patients with severe hepatic insufficiency
Patients experiencing an acute transmural infarction at the time of the index visit
Conditions that are known to affect resistive vessel function or myocardial flow